Incap's Q4 net sales and adjusted EBIT margin beat consensus (LSEG Data & Analytics) expectations.
A weak market environment and weak cargo tonnes have taken the share price to an all-time low in Feb...
Ferronordic's Q4 2023 results were a mixed bag, coming in somewhat below our expectations.
Atria's Q4 adjusted EBIT of EUR 9.4m fell clearly short of LSEG Data & Analytics consensus expectati...
Robust guidance with earnings outlook ahead of expectations New CEO a passion for ESG and on deliver...
First Venture publicerade den 22 februari 2024 bolagets delårsrapport för det fjärde kvartalet av 20...
Huddlestock published on February the 22nd, the company’s quarterly report for the fourth quarter 20...
Redeye thinks FlexQube’s Q4 report was better than expected due to the high gross margin and the cos...
Redeye leaves a comment following Newbury Pharmaceuticals’ announcement earlier today regarding a ne...
NOSIUM har publicerat bolagets delårsrapport för det fjärde kvartalet 2023.
Redeye is happy to see the announcement of Bong receiving some significant new business contracts fo...
Redeye gives a short comment on the exciting news that the FDA and IRLAB have an aligned view on a f...
FY23 was a year with numerous obstacles for the European paper and pulp industry, including lower de...
Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) concludes a transformative 2023, ...
Redeye reinforces its positive view on CombinedX following the acquisition of M3CS.
Högre motiverat värde Vi höjer vårt motiverade värde till 49-59 kr (43-53) per aktie på grund av ett...
Net sales was 7% above consensus (LSEG) in Q4. Also adjusted EBIT margin of 10.
Redeye updates its view of Nanexa following the Q4 report and recent events in the company.
Northbaze Q4 report came in under our estimate and the company continues to strugle in a difficult e...
Sales SEK 553m -8% vs. ABGSCe 599m Adj. EBIT ~SEK -5m vs.
